Bio-Rad Laboratories, Inc.
BIO
Pozycja w akcjach
#2167
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules,... Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Cena akcji
$352.07
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$9.41B
Zmiana (1 dzień)
-0.23%
Zmiana (1 rok)
9.37%
Kraj
US
Handel Bio-Rad Laboratories, Inc. (BIO)
Kategoria
Healthcare
Wskaźnik P/E dla Bio-Rad Laboratories, Inc. (BIO)
Wskaźnik P/E na dzień October 2026 TTM: 43.51
Według najnowszych raportów finansowych i ceny akcji Bio-Rad Laboratories, Inc., obecny wskaźnik P/E (TTM) wynosi 43.51. Na koniec 2023 wskaźnik P/E wynosił -14.80.
Historia wskaźnika P/E dla Bio-Rad Laboratories, Inc. od 2000 do 2026
Wskaźnik P/E na koniec każdego roku
| Rok | Wskaźnik P/E | Zmień |
|---|---|---|
| 2026 (TTM) | 43.51 | -964.99% |
| 2024 | -5.03 | -66.04% |
| 2023 | -14.80 | 328.61% |
| 2022 | -3.45 | -165.17% |
| 2021 | 5.30 | 16.45% |
| 2020 | 4.55 | -27.54% |
| 2019 | 6.28 | -67.28% |
| 2018 | 19.19 | -68.89% |
| 2017 | 61.69 | -67.67% |
| 2016 | 190.80 | 433.20% |
| 2015 | 35.78 | -8.68% |
| 2014 | 39.18 | -13.74% |
| 2013 | 45.42 | 158.67% |
| 2012 | 17.56 | 16.26% |
| 2011 | 15.11 | -2.48% |
| 2010 | 15.49 | -15.26% |
| 2009 | 18.28 | -19.87% |
| 2008 | 22.81 | -23.37% |
| 2007 | 29.77 | 41.23% |
| 2006 | 21.08 | 0.79% |
| 2005 | 20.91 | -3.29% |
| 2004 | 21.63 | 12.38% |
| 2003 | 19.24 | 34.25% |
| 2002 | 14.33 | -18.83% |
| 2001 | 17.66 | 41.42% |
| 2000 | 12.49 | 0.00% |
Wskaźnik P/E dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/E | Różnica wskaźnika P/E | Kraj |
|---|---|---|---|
| 33.11 | -23.90% |
US
|
|
| 21.39 | -50.84% |
IE
|
|
| 28.94 | -33.47% |
US
|
|
| 17.34 | -60.15% |
US
|
|
| - | - |
DE
|
Jak odczytywać wskaźnik P/E?
Wskaźnik Cena/Zysk (P/E) mierzy relację między ceną akcji firmy a jej zyskiem na akcję.
Niski, ale dodatni P/E oznacza firmę osiągającą wysokie zyski względem obecnej wyceny i może być niedowartościowana. Wysoki ujemny (bliski 0) P/E wskazuje na duże straty.
Firmy z P/E powyżej 30 lub ujemnym uznaje się zazwyczaj za "akcje wzrostowe", czyli inwestorzy oczekują wzrostu lub przyszłych zysków.
Firmy z dodatnim P/E poniżej 10 uznaje się za "akcje wartościowe", co oznacza, że są już bardzo dochodowe, ale bez dużego potencjału wzrostu.